{
    "clinical_study": {
        "@rank": "138067", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive adefovir dipivoxil and L-carnitine"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive adefovir dipivoxil placebo and L-carnitine."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of adefovir dipivoxil in prolonging survival of patients\n      with advanced HIV disease. In CMV prophylaxis substudy: To evaluate the efficacy of adefovir\n      dipivoxil in preventing the development of CMV end-organ disease in patients with advanced\n      HIV coinfected with CMV.\n\n      The optimal treatment for HIV infection and the prevention of CMV disease has not been\n      identified. Currently available antiretroviral therapies are hampered by both significant\n      toxicities and the development of resistance. In addition, agents for preventing CMV\n      disease, such as oral ganciclovir, are complicated by poor bioavailability and decreased\n      compliance secondary to toxicities. Moreover, discordant results have been reported\n      regarding the effectiveness of oral ganciclovir for preventing CMV disease. There is a need\n      for newer agents with anti-HIV and anti-herpesvirus activity that have good pharmacokinetic\n      and safety profiles and that will be well tolerated by patients. Adefovir dipivoxil is an\n      oral pro-drug of PMEA, a nucleoside analog with activity against a broad spectrum of\n      retroviruses and herpesviruses, including important human pathogens, such as HIV-1, HIV-2\n      and CMV. Due to its anti-HIV and anti-herpesvirus activity, adefovir dipivoxil may be able\n      to decrease the incidence of opportunistic herpesvirus infections and prolong survival in\n      patients with advanced HIV infection."
        }, 
        "brief_title": "The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients", 
        "completion_date": {
            "#text": "August 1999", 
            "@type": "Actual"
        }, 
        "condition": [
            "Cytomegalovirus Infections", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Cytomegalovirus Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "The optimal treatment for HIV infection and the prevention of CMV disease has not been\n      identified. Currently available antiretroviral therapies are hampered by both significant\n      toxicities and the development of resistance. In addition, agents for preventing CMV\n      disease, such as oral ganciclovir, are complicated by poor bioavailability and decreased\n      compliance secondary to toxicities. Moreover, discordant results have been reported\n      regarding the effectiveness of oral ganciclovir for preventing CMV disease. There is a need\n      for newer agents with anti-HIV and anti-herpesvirus activity that have good pharmacokinetic\n      and safety profiles and that will be well tolerated by patients. Adefovir dipivoxil is an\n      oral pro-drug of PMEA, a nucleoside analog with activity against a broad spectrum of\n      retroviruses and herpesviruses, including important human pathogens, such as HIV-1, HIV-2\n      and CMV. Due to its anti-HIV and anti-herpesvirus activity, adefovir dipivoxil may be able\n      to decrease the incidence of opportunistic herpesvirus infections and prolong survival in\n      patients with advanced HIV infection.\n\n      All patients will be enrolled within the first 18 months of the study. They will be\n      randomized to 1 of 2 groups. Group 1 will be comprised of 1080 patients and will receive\n      adefovir dipivoxil plus L-carnitine and group 2 will be comprised of 1080 patients and will\n      receive a placebo plus  L-carnitine. At least the first 400 patients enrolled (200 in each\n      group) will comprise the safety-HIV virology cohort. These patients will have more frequent\n      follow up visits, additional laboratory evaluations, and more intensive safety data\n      information during the first 6 months. NOTE: At least 850 patients who are infected with CMV\n      are followed for the development of CMV end-organ disease in a CMV prophylaxis substudy.\n\n      AS PER AMENDMENT 8/7/97: All patients are enrolled in the primary study and randomized to\n      the treatment or placebo regimen. Within the primary study, patients meeting specified\n      criteria may be enrolled in one or more of the following cohorts:\n\n        1. Safety-HIV virology cohort (at least the first 400 patients enrolled in the study\n           regardless of CMV status).\n\n        2. CMV bDNA cohort (those patients in the safety-HIV virology cohort who are\n           CMV-positive).\n\n        3. CMV-virology cohort (the first 400 patients in the CMV bDNA cohort enrolled at sites\n           able to obtain CMV urine cultures).\n\n      All patients who are CMV-positive are enrolled in the CMV prophylaxis substudy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Chronically administered concomitant therapies for HIV and opportunistic diseases,\n             including chemotherapy for cutaneous Kaposi's sarcoma, must be on these therapies for\n             at least 30 days prior to study entry.\n\n          -  Short courses of oral antibiotics or other therapies given for a limited period of 3\n             weeks.\n\n          -  Episodic use of IV acyclovir or oral acyclovir > 1g/day for treatment of acute\n             illness is permitted at the clinician's discretion.\n\n        Patients must have:\n\n          -  A working diagnosis of HIV infection based on the patient's medical history,\n             behavioral history, clinical signs and symptoms, or results of other laboratory\n             tests.\n\n          -  CD4+ cell count <= 100 cells/mm3 within 60 days prior to randomization (OR, AS PER\n             AMENDMENT 8/7/97, a CD4+ cell count that is both > 100 and <= 200 cells/mm3 within 60\n             days prior to randomization and a documented nadir CD4+ cell count <= 50 cells/ mm3\n             at any time prior to randomization).\n\n          -  Reasonably good health.\n\n          -  Life expectancy of at least 6 months.\n\n          -  Access to a refrigerator for the storage of adefovir dipivoxil.\n\n          -  Signed informed consent from parent or legal guardian for patients less than 18 years\n             of age.\n\n        AS PER AMENDMENT 8/7/97:\n\n          -  CMV serology (IgG) positive (CMV bDNA cohort and CMV-virology cohort).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Evidence of active CMV disease at screening.\n\n          -  Conditions that would require use of medications listed in Exclusion Concurrent\n             Medications.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Any investigational anti-CMV agent.\n\n          -  Adenine arabinoside (vidarabine).\n\n          -  Amantadine hydrochloride (Symmetrel).\n\n          -  Cidofovir (Vistide).\n\n          -  CMV hyperimmune globulin.\n\n          -  Cytosine arabinoside (cytarabine).\n\n          -  Famciclovir.\n\n          -  Foscarnet (phosphonoformic acid).\n\n          -  Ganciclovir (Cytovene).\n\n          -  GW 1263W94 (Benzamidazole).\n\n          -  Idoxuridine.\n\n          -  Intravenous acyclovir.\n\n          -  ISIS 2922 (Anti-sense).\n\n          -  Lobucavir.\n\n          -  MSL109.\n\n          -  Oral acyclovir > 1 g/day.\n\n          -  Valacyclovir.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of CMV end-organ disease.\n\n        Prior Medication:\n\n        Excluded within 2 weeks of randomization:\n\n          -  Any investigational anti-CMV agent.\n\n          -  Adenine arabinoside (vidarabine).\n\n          -  Amantadine hydrochloride (Symmetrel).\n\n          -  Cidofovir (Vistide).\n\n          -  CMV hyperimmune globulin.\n\n          -  Cytosine arabinoside (cytarabine).\n\n          -  Famciclovir.\n\n          -  Ganciclovir (Cytovene).\n\n          -  GW 1263W94 (Benzamidazole).\n\n          -  Idoxuridine.\n\n          -  Intravenous acyclovir.\n\n          -  ISIS 2922 (Anti-sense).\n\n          -  Lobucavir.\n\n          -  MSL109.\n\n          -  Oral acyclovir > 1 g/day.\n\n          -  Valacyclovir.\n\n        Excluded within 60 days prior to study entry:\n\n          -  Foscarnet."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "505", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001082", 
            "org_study_id": "CPCRA 039", 
            "secondary_id": "11589"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1", 
                    "2"
                ], 
                "description": "500 mg tablet taken orally daily", 
                "intervention_name": "Levocarnitine", 
                "intervention_type": "Drug", 
                "other_name": "L-carnitine"
            }, 
            {
                "arm_group_label": "1", 
                "description": "120 mg tablet taken orally daily", 
                "intervention_name": "Adefovir dipivoxil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2", 
                "description": "Oral placebo tablet taken daily", 
                "intervention_name": "Adefovir dipivoxil placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carnitine", 
                "Adefovir", 
                "Adefovir dipivoxil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Cytomegalovirus Infections", 
            "Antiviral Agents", 
            "CD4 Lymphocyte Count", 
            "Prodrugs", 
            "Survival", 
            "Adenine"
        ], 
        "lastchanged_date": "September 28, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "Community Consortium / UCSF"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80204"
                    }, 
                    "name": "Denver CPCRA / Denver Public Hlth"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20422"
                    }, 
                    "name": "Washington Reg AIDS Prog / Dept of Infect Dis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "AIDS Research Consortium of Atlanta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60657"
                    }, 
                    "name": "AIDS Research Alliance - Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "Louisiana Comm AIDS Rsch Prog / Tulane Univ Med"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Henry Ford Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Wayne State Univ - WSU/DMC / Univ Hlth Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Camden", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08103"
                    }, 
                    "name": "Southern New Jersey AIDS Cln Trials / Dept of Med"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07103"
                    }, 
                    "name": "North Jersey Community Research Initiative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87131"
                    }, 
                    "name": "Partners in Research / New Mexico"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10037"
                    }, 
                    "name": "Harlem AIDS Treatment Grp / Harlem Hosp Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "The Research and Education Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Philadelphia FIGHT"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23298"
                    }, 
                    "name": "Richmond AIDS Consortium / Div of Infect Diseases"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil (Bis-POM PMEA) in Prolonging Survival of HIV-Infected Individuals With a CD4+ Cell Count of <= 100/mm3 or With a CD4+ Cell Count Both > 100 and <= 200/mm3 and a Nadir CD4+ Cell Count of <= 50/mm3", 
        "overall_official": [
            {
                "last_name": "Brosgart C", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Fisher E", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 1999", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Morbidity", 
            "safety_issue": "Yes", 
            "time_frame": "Throughout study"
        }, 
        "reference": [
            {
                "citation": "Fisher E, Brosgart C, Cohn D, Chaloner K, Pulling C, Alston B, Schmetter B, El-Sadr W. Placebo (PLC)-controlled, multicenter trial of adefovir dipivoxil (ADV) in patients (pt) with HIV disease. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:160 (abstract no 491)"
            }, 
            {
                "citation": "Brosgart C, Fisher E, Pulling C, Chaloner K, Cohn D, Elsadr W, Verheggen R, Schmetter B, Alston B. Prevalence of asymptomatic CMV retinitis (CMVR) in AIDS patients. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:152 (abstract no 453)"
            }, 
            {
                "citation": "Fisher E, Brosgart C, Cohn D, Chaloner K, Pulling C, Schmetter B, Alston B, El-Sadr W. Safety of adefovir dipivoxil (ADV) and incidence of proximal renal tubular disorder (PRTD) in a placebo (PLC)-controlled trial in patients (pt) with advanced HIV disease. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:195 (abstract no 678)"
            }, 
            {
                "citation": "Brosgart C, Pulling C, Chaloner K, Fisher E, Coakley D, Diggins M, Ivannidis J. Serum carnitine levels in AIDS patients with advanced HIV disease from the CPCRA 039 trial. Int Conf AIDS. 1998;12:1094 (abstract no 60508)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001082"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 1996", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }, 
    "geocoordinates": {
        "AIDS Research Alliance - Chicago": "41.878 -87.63", 
        "AIDS Research Consortium of Atlanta": "33.749 -84.388", 
        "Community Consortium / UCSF": "37.775 -122.419", 
        "Denver CPCRA / Denver Public Hlth": "39.739 -104.985", 
        "Harlem AIDS Treatment Grp / Harlem Hosp Ctr": "40.714 -74.006", 
        "Henry Ford Hosp": "42.331 -83.046", 
        "Louisiana Comm AIDS Rsch Prog / Tulane Univ Med": "29.951 -90.072", 
        "North Jersey Community Research Initiative": "40.736 -74.172", 
        "Partners in Research / New Mexico": "35.084 -106.651", 
        "Philadelphia FIGHT": "39.952 -75.164", 
        "Richmond AIDS Consortium / Div of Infect Diseases": "37.541 -77.436", 
        "Southern New Jersey AIDS Cln Trials / Dept of Med": "39.926 -75.12", 
        "The Research and Education Group": "45.523 -122.676", 
        "Washington Reg AIDS Prog / Dept of Infect Dis": "38.895 -77.036", 
        "Wayne State Univ - WSU/DMC / Univ Hlth Ctr": "42.331 -83.046"
    }
}